Slide 1: Next Generation Chemotherapy: Improved Treatment for More Patients
@ Processa Pharmaceuticals Next Generation Chemotherapy: Improved Treatment for More Patients Corporate Presentation January 2024
Slide 2: Forward Looking Statement and Disclosures
Forward Looking Statement and Disclosures @ Processa Pharmaceuticals This presentation includes forward-looking statements based upon our current expectations. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predi
Slide 3: About Processa Pharmaceuticals
About Processa Pharmaceuticals @ Processa Pharmaceuticals Next-Generation Chemotherapies (NGCs) Designed to Improve Survival and Quality of Life for Cancer Patients * Ade-risked strategy of developing new chemical entities (NCEs) Processa Pharmaceuticals based on improving pharmacokinetics of existi
Slide 4: Processa Senior Management
Processa Senior Management George Ng Chief Executive Officer Joined Processa 2023, Former Roles + President, COO, & Director, Caidi Biotherapeutics + Partner, PENG Life Science Ventures Founder and President, Scilex Pharmaceuticals 1D, University of Notre Dame; B.A.S. Dual Degree, University of Cali
Slide 5: Oncology Opportunity
Oncology Opportunity * More than 200,000 new cancer diagnoses worldwide across multiple indications for each NGC in development. * NGC compounds will potentially address efficacy and toxicity at an optimized dose to show improvement over standard of care. * Development process aligns with FDA’s Onco
Slide 6: Processa's Pipeline
Processa’s Pipeline Drug Next Generation Capecitabine (Pcs6422) Next Generation Gemcitabine (Pcs3117) Next Generation Irinotecan (Pcs117) NASDAQ: PCSA Processa Pharmaceuticals Next Generation Development Stage Cancer Indications Preclin Phase1 Phase2 Phase3 NDA Colorectal, Breast, Hepatocellular, Pa
Slide 7: How Our Oncology Assets Differ from Current Chemotherapy
@ Processa Pharmaceuticals How Our Oncology Assets Differ from Current Chemotherapy Capecitabine — Low treatment response with high side effect profile. Gemcitabine —High drug resistance and/or acquired resistance; administered as IV. lrinotecan — Significant side-effect profile limits dosing and dr
Slide 8: PCS6422 / Next Generation Capecitabine (NGC-Cap)
PCS6422 / Next Generation Capecitabine (NGC-Cap) Efficacy Side Effects Clinical Development IVASDAQ: PCSA @ Processa Pharmaceuticals Alters metabolism to increase distribution of 5-FU and cancer-killing molecules to cancer cells while reducing the metabolites that only cause side effects Active mole
Slide 9: NGC-Cap Not the Same Treatment or Drug as FDA-Approved Capecitabine
NGC-Cap Not the Same Treatment or Drug as @ Processa Pharmaceuticals FDA-Approved Capecitabine Capecitabine (Xeloda®) NGC-Cap 10% - 20% to ~ 75% - 85% to FBAL ~ 80% - 90% to GD) Formation of Anabolites Catabolite Anabolies FBAL Cancer-Killing Related Side Effects (e.g, HFS) _ Gataboites & i ‘emporar
Slide 10: PCS3117 / Next Generation Gemcitabine (NGC-Gem)
PCS3117 / Next Generation Gemcitabine (NGC-Gem) Process Pharmacol Oral Drug with Same MOA as Gemcitabine * Provides improved treatment over Gemcitabine seen in previous pancreatic Efficacy cancer trial data; cancer cells exposed to more NGC-Gem cancer-killing molecules given more activating enzyme S
Slide 11: NGC-Gem (Oral): Increase Metabolism to Cancer-Killing Molecules
NGC-Gem (Oral): Increase Metabolism to Cancer-Killing @ Processa Pharmaceuticals Molecules Given Different Metabolizing Enzyme than Gemcitabine (IV) Active Cancer Active Cancer Ho. weed Killing Molecules Killing Molecules be Gemcitabine (dFdC) IV Administration NGC-Gem Oral Paani In Some Cancers Adm
Slide 12: PCS11T / Next Generation Irinotecan (NGC-Iri)
@ Processa Pharmaceuticals PCS11T / Next Generation Irinotecan (NGC-Iri) * Active molecule SN-38 is same active molecule in Irinotecan Efficacy * Distributes SN-38 differently, entering the cell membrane of cancer cells preferentially over normal cells, improving cancer-killing effect * Given MNM-SN
Slide 13: Tumor-Bearing Mice Had 200x Higher Drug In Tumor vs Muscle
Tumor-Bearing Mice Had 200x Higher Drug In ‘Tumor vs Muscle Compared To 15x With Irinotecan NGC Irinotecan: Higher Amounts & Lower Required Dose @ Processa Pharmaceuticals Efficacy Maintained at Lower Doses of NGC-Iri When Compared to Irinotecan in SW620 Colorectal Cancer Xenograft Irinotecan Tumor/
Slide 14: Summary of Activities/Milestones
Summary of Activities/Milestones @ Provessa Pharmaceuticals Milestone Approx. Date NGC-Cap: Cohort Review Committee Meeting to Determine if Phase 1B MTD Trial Enrollment Completed January 2024 NGC-Cap: Finish Defining Regulatory Paths to Approval and ODR Phase 2 Design based on FDA aoe. Communicatio
Slide 15: Why Processa Now?
@ Processa Pharmaceuticals Why Processa Now? * Upcoming Catalysts/Milestones: ~ PCS6422/NGC-Cap Qs Wy — Complete Phase 1B enrollment & dose regimen safety evaluation. “i Pp \ — Finalize Phase 2 study design based on FDA feedback. ~ Initiate Phase 2 study and patient enrollment. — PCS3117/NGC-Gem x -
Slide 16: Company Summary
Company Summary @ rrovessa Pharmaceuticals Up-Side Opportunity with a Strategy of Optimizing Proven Therapeutics via NCEs * Developing Next-Generation Chemotherapy (NGC) drugs with near term achievable milestones using cancer-killing molecules presently in FDA-approved drugs. * NCEs with potential f
Slide 17: Investor & Media Relations
Investor & Media Relations: CORE IR IR@processapharma.com oe